Microfluidics International Corporation (OTCBB: MFLU) today announced that, along with its exclusive Japanese distributor, POWREX Corporation, it has introduced Microfluidics Reaction Technology (MRT) to Japan as the world's only viable large-scale, bottom-up technology for nanoparticle creation.
MRT is a revolutionary platform which enables continuous pharmaceutical manufacturing via crystallization and multi-phase chemical reactions.
POWREX is one of the largest providers of technology to the pharmaceutical industry in Japan. The announcement was made at the POWREX Symposium in Osaka this week and at a press conference to be held on April 21, 8:30 AM, at INTERPHEX 2010 in Manhattan.
"Japanese companies and researchers are visionary innovators, and we are pleased to offer them the latest nanomaterials processing methods available to achieve new goals," said Takeshi Takashima, President of POWREX. "Our strong partnership with Microfluidics enables us to bring this innovative and important technology to potential customers in Japan."
The technology has immediate value in pharmaceutical industry, such as creating more effective and targeted drugs. Japan is the second-largest single-country pharmaceutical market in the world.
"MRT allows companies to improve bioavailability, target delivery and encapsulate actives more efficiently than any top-down process or traditional crystallization method," said Thomai "Mimi" Panagiotou, PhD., Microfluidics Chief Technology Officer. "Importantly, its innovative capabilities for continuous crystallization and chemical reactions have the potential to transform the manufacture of drugs and chemicals by significantly streamlining the steps, timing and cost of consistent, continuous large-scale commercial production."
Microfluidics Japanese Patent Application
Microfluidics has applied for a Japanese patent on MRT entitled "Apparatus and Methods for Nanoparticle Generation and Process Intensification of Transport and Reaction Systems." This is the first time that the Company has filed for this type of charter outside of the United States.
"Because we have such confidence in our valued partner, POWREX, we are filing for a patent and are eager to introduce this revolutionary platform technology to Japan," said Michael C. Ferrara, President and CEO of Microfluidics. "MRT enables pharmaceutical companies interested in continuous manufacturing to break new ground in crystallization and nanotechnology application development. POWREX engineers have been well trained to understand how to make the most of the results through a combination of a unique processor and expert process development skills. Their collective experience and dedication in the pharmaceutical, biotechnology and energy industries will align their customers for success."